



UnitedHealthcare Pharmacy  
Clinical Pharmacy Programs

|                   |                                   |
|-------------------|-----------------------------------|
| Program Number    | 2018 P 3083-4                     |
| Program           | Step Therapy – Essential PDL Only |
| Medication        | Azilect (rasagiline)              |
| P&T Approval Date | 10/2016, 10/2017, 10/2018         |
| Effective Date    | 2/1/2019;<br>Oxford: N/A          |

**1. Background:**

Step Therapy programs are utilized to encourage the use of lower cost alternatives for certain therapeutic classes. This program requires a member to try the lower cost generic alternative before coverage will be provided for brand Azilect.

**2. Coverage Criteria<sup>a</sup>:**

|  |
|--|
| <p>A. <b>Azilect</b> will be approved based on the following criterion:</p> <ol style="list-style-type: none"> <li>1. History of failure, contraindication, or intolerance to the following (list reason for therapeutic failure, contraindication, or intolerance):           <ol style="list-style-type: none"> <li>a. selegiline (generic Eldepryl)</li> </ol> </li> </ol> <p style="text-align: center;"><b>Authorization will be issued for 12 months</b></p> <p><sup>a</sup> State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply</p> |
|--|

**3. Additional Clinical Rules:**

- Supply limits may be in place

**4. References:**

1. Azilect Prescribing Information. Teva Neuroscience. Overland Park, KS. June 2018.

|                       |   |
|-----------------------|---|
| Program               | Step Therapy – Azilect  |
| <b>Change Control</b> |   |
| Date                  | Change  |
| 10/2016               | New program.  |
| 1/2017                | Administrative change. Clarified applies to Essential PDL only. |
| 10/2017               | Annual review. State mandate reference language updated.        |
| 10/2018               | Annual review. Updated references.                              |